Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.
The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.
The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback